Literature DB >> 11533918

Hemodialysis in the pediatric patient: state of the art.

S L Goldstein1.   

Abstract

The prevalence of pediatric patients receiving hemodialysis as renal replacement therapy has increased over the past decade. Although numerous technologic advances have been developed and their impact assessed for adult patients receiving hemodialysis, no long-term outcome study currently exists for children receiving hemodialysis. Barriers to such study include the necessity for long-term multicenter participation to enroll enough patients to make definitive statements regarding outcome, lack of consensus for an acceptable and practical method for hemodialysis adequacy measurement in children, and the need for pediatric end-stage renal disease (ESRD)-specific tools for assessment of quality of life. The first part of this article reviews issues surrounding hemodialysis adequacy measurement in children. In particular, simple but accurate Kt/V and normalized protein catabolic rate (nPCR) estimation methods are proposed that should allow for more widespread use of Kt/V and nPCR for measurement of urea clearance and nutritional status in children receiving hemodialysis, important for both patient care and to control for hemodialysis adequacy in pediatric outcome studies. In addition, the principles and pediatric study of 2 technologic advances, continuous noninvasive monitoring of hematocrit and noninvasive ultrasound dilution vascular access flow measurement, are reviewed. Finally, suggestions are provided for future study pertinent to both short-term and long-term outcomes in children receiving hemodialysis. Copyright 2001 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11533918     DOI: 10.1053/jarr.2001.26347

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  8 in total

1.  Two-point normalized protein catabolic rate overestimates nPCR in pediatric hemodialysis patients.

Authors:  Poyyapakkam R Srivaths; Scott Sutherland; Steven Alexander; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2012-12-02       Impact factor: 3.714

2.  Short stature and growth hormone use in pediatric hemodialysis patients.

Authors:  Gregory Gorman; Barbara Fivush; Diane Frankenfield; Bradley Warady; Sandra Watkins; Andrew Brem; Alicia Neu
Journal:  Pediatr Nephrol       Date:  2005-08-18       Impact factor: 3.714

3.  Growth in adolescent hemodialysis patients: data from the Centers for Medicare & Medicaid Services ESRD Clinical Performance Measures Project.

Authors:  Alicia M Neu; Marjorie Bedinger; Barbara A Fivush; Bradley A Warady; Sandra L Watkins; Aaron L Friedman; Andrew S Brem; Stuart L Goldstein; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

4.  Hospitalization rates and clinical performance measures in U.S. adolescent hemodialysis patients.

Authors:  Gregory Gorman; Alicia Neu; Barbara Fivush; Diane Frankenfield; Susan Furth
Journal:  Pediatr Nephrol       Date:  2010-07-29       Impact factor: 3.714

Review 5.  Nutrition aspects in children receiving maintenance hemodialysis: impact on outcome.

Authors:  Poyyapakkam R Srivaths; Craig Wong; Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2008-02-22       Impact factor: 3.714

6.  Decisions concerning potentially life-sustaining treatments in paediatric nephrology: a multicentre study in French-speaking countries.

Authors:  Isabelle Fauriel; Grégoire Moutel; Marie-Laure Moutard; Luc Montuclard; Nathalie Duchange; Ingrid Callies; Irène François; Pierre Cochat; Christian Hervé
Journal:  Nephrol Dial Transplant       Date:  2004-02-19       Impact factor: 5.992

7.  Linear growth in pediatric hemodialysis patients.

Authors:  Gregory Gorman; Diane Frankenfield; Barbara Fivush; Alicia Neu
Journal:  Pediatr Nephrol       Date:  2007-10-16       Impact factor: 3.714

8.  Outcomes of Hemodialysis in Children: A 35-Year Experience at Severance Hospital.

Authors:  Hyun-Seung Shin; Ji Young Oh; Se Jin Park; Ji Hong Kim; Jae Seung Lee; Jae Il Shin
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.